1. Validation of self-reported sun exposure against electronic ultraviolet radiation dosimeters.
- Author
-
Zhang, Ran, Smit, Amelia K, Espinoza, David, Allen, Martin, Reyes-Marcelino, Gillian, Kimlin, Michael G, Lo, Serigne N, Sharman, Ashleigh R, Law, Matthew H, Kanetsky, Peter A, Mann, Graham J, and Cust, Anne E
- Subjects
- *
SUNSHINE , *DOSIMETERS , *BLAND-Altman plot , *ULTRAVIOLET radiation , *ULTRAVIOLET radiation measurement , *SOLAR ultraviolet radiation - Abstract
From the dosimeter data we derived: (i) time spent outdoors exposed to UV, defined as any 8-s measurements with UV values of >0; and (ii) total standard erythemal doses (SEDs) as a measure of UV dose. Table 1 Spearman rank correlations between weekend and weekday ultraviolet radiation (UV) exposure measured as standard erythemal doses (SEDs) using electronic UV dosimeters HT
. Validation, exposure measurement, ultraviolet radiation, dosimetry, questionnaire, skin cancer Keywords: Validation; exposure measurement; ultraviolet radiation; dosimetry; questionnaire; skin cancer EN Validation exposure measurement ultraviolet radiation dosimetry questionnaire skin cancer 324 328 5 02/16/23 20230201 NES 230201 Ultraviolet radiation (UV) exposure is the main risk factor for skin cancer[1] and skin cancer prevention research and health promotion programme evaluation relies on the accurate measurement of sun exposure using questionnaires. [Extracted from the article] - Published
- 2023
- Full Text
- View/download PDF
2. Communicating Personal Melanoma Polygenic Risk Information: Participants' Experiences of Genetic Counseling in a Community-Based Study.
- Author
-
Smit, Amelia K., Espinoza, David, Fenton, Georgina L., Kirk, Judy, Innes, Jessica S., McGovern, Michael, Limb, Sharne, Turbitt, Erin, and Cust, Anne E.
- Subjects
- *
MONOGENIC & polygenic inheritance (Genetics) , *GENETIC counseling , *HEALTH literacy , *MELANOMA , *TELEPHONE calls - Abstract
Personalized polygenic risk information may be used to guide risk-based melanoma prevention and early detection at a population scale, but research on communicating this information is limited. This mixed-methods study aimed to assess the acceptability of a genetic counselor (GC) phone call in communicating polygenic risk information in the Melanoma Genomics Managing Your Risk randomized controlled trial. Participants (n = 509) received personalized melanoma polygenic risk information, an educational booklet on melanoma prevention, and a GC phone call, which was audio-recorded. Participants completed the Genetic Counseling Satisfaction Survey 1-month after receiving their risk information (n = 346). A subgroup took part in a qualitative interview post-study completion (n = 20). Survey data were analyzed descriptively using SPSS, and thematic analysis of the qualitative data was conducted using NVivo 12.0 software. The survey showed a high level of acceptability for the GC phone call (mean satisfaction score overall: 4.3 out of 5, standard deviation (SD): 0.6) with differences according to gender (mean score for women: 4.4, SD: 0.6 vs. men: 4.2, SD: 0.7; p = 0.005), health literacy (lower literacy: 4.1, SD: 0.8; average: 4.3, SD: 0.6; higher: 4.4, SD: 0.6: p = 0.02) and polygenic risk group (low risk: 4.5, SD: 0.5, SD: average: 4.3, SD: 0.7, high: 4.3, SD: 0.7; p = 0.03). During the GC phone calls, the discussion predominately related to the impact of past sun exposure on personal melanoma risk. Together our findings point to the importance of further exploring educational and support needs and preferences for communicating personalized melanoma risk among population subgroups, including diverse literacy levels. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Knowledge, views and expectations for cancer polygenic risk testing in clinical practice: A cross‐sectional survey of health professionals.
- Author
-
Smit, Amelia K., Sharman, Ashleigh R., Espinoza, David, Wallingford, Courtney, Young, Mary‐Anne, Dunlop, Kate, Tiller, Jane, Newson, Ainsley J., Meiser, Bettina, Cust, Anne E., and Yanes, Tatiane
- Subjects
- *
MEDICAL personnel , *DISEASE risk factors , *HEALTH surveys , *GENERAL practitioners , *QUESTIONNAIRES - Abstract
Polygenic risk scores (PRS) are becoming increasingly available in clinical practice to evaluate cancer risk. However, little is known about health professionals' knowledge, attitudes, and expectations of PRS. An online questionnaire was distributed by relevant health professional organisations predominately in Australia, Canada and the US to evaluate health professionals' knowledge, views and expectations of PRS. Eligible participants were health professionals who provide cancer risk assessments. Results from the questionnaire were analysed descriptively and content analysis was undertaken of free‐text responses. In total, 105 health professionals completed the questionnaire (genetic counsellors 84%; oncologists 6%; clinical geneticists 4%; other 7%). Although responses differed between countries, most participants (61%) had discussed PRS with patients, 20% had ordered a test and 14% had returned test results to a patient. Confidence and knowledge around interpreting PRS were low. Although 69% reported that polygenic testing will certainly or likely influence patient care in the future, most felt unprepared for this. If scaled up to the population, 49% expect that general practitioners would have a primary role in the provision of PRS, supported by genetic health professionals. These findings will inform the development of resources to support health professionals offering polygenic testing, currently and in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial.
- Author
-
Ackermann, Deonna M., Smit, Amelia K., Janda, Monika, van Kemenade, Cathelijne H., Dieng, Mbathio, Morton, Rachael L., Turner, Robin M., Cust, Anne E., Irwig, Les, Hersch, Jolyn K., Guitera, Pascale, Soyer, H. Peter, Mar, Victoria, Saw, Robyn P. M., Low, Donald, Low, Cynthia, Drabarek, Dorothy, Espinoza, David, Emery, Jon, and Murchie, Peter
- Subjects
- *
HEALTH care reminder systems , *CLINICAL trial registries , *MELANOMA , *RANDOMIZED controlled trials , *INSTRUCTIONAL films , *LED displays - Abstract
Background: Most subsequent new primary or recurrent melanomas might be self-detected if patients are trained to systematically self-examine their skin and have access to timely medical review (patient-led surveillance). Routinely scheduled clinic visits (clinician-led surveillance) is resource-intensive and has not been shown to improve health outcomes; fewer visits may be possible if patient-led surveillance is shown to be safe and effective. The MEL-SELF trial is a randomised controlled trial comparing patient-led surveillance with clinician-led surveillance in people who have been previously treated for localised melanoma.Methods: Stage 0/I/II melanoma patients (n = 600) from dermatology, surgical, or general practice clinics in NSW Australia, will be randomised (1:1) to the intervention (patient-led surveillance, n = 300) or control (usual care, n = 300). Patients in the intervention will undergo a second randomisation 1:1 to polarised (n = 150) or non-polarised (n = 150) dermatoscope. Patient-led surveillance comprises an educational booklet, skin self-examination (SSE) instructional videos; 3-monthly email/SMS reminders to perform SSE; patient-performed dermoscopy with teledermatologist feedback; clinical review of positive teledermoscopy through fast-tracked unscheduled clinic visits; and routinely scheduled clinic visits following each clinician's usual practice. Clinician-led surveillance comprises an educational booklet and routinely scheduled clinic visits following each clinician's usual practice. The primary outcome, measured at 12 months, is the proportion of participants diagnosed with a subsequent new primary or recurrent melanoma at an unscheduled clinic visit. Secondary outcomes include time from randomisation to diagnosis (of a subsequent new primary or recurrent melanoma and of a new keratinocyte cancer), clinicopathological characteristics of subsequent new primary or recurrent melanomas (including AJCC stage), psychological outcomes, and healthcare use. A nested qualitative study will include interviews with patients and clinicians, and a costing study we will compare costs from a societal perspective. We will compare the technical performance of two different models of dermatoscope (polarised vs non-polarised).Discussion: The findings from this study may inform guidance on evidence-based follow-up care, that maximises early detection of subsequent new primary or recurrent melanoma and patient wellbeing, while minimising costs to patients, health systems, and society.Trial Registration: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12621000176864 . Registered on 18 February 2021. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
5. Family communication about genomic sequencing: A qualitative study with cancer patients and relatives.
- Author
-
Smit, Amelia K, Bartley, Nicci, Best, Megan C, Napier, Christine E, Butow, Phyllis, Newson, Ainsley J, Tucker, Kathy, Ballinger, Mandy L, Thomas, David M, Jacobs, Chris, Meiser, Bettina, Goldstein, David, Savard, Jacqueline, Juraskova, Ilona, and PiGeOn authorship group
- Subjects
- *
FAMILY communication , *CANCER patients , *QUALITATIVE research , *MEDICAL personnel , *COMMUNICATIVE disorders , *RESEARCH , *RESEARCH methodology , *FAMILIES , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *COMMUNICATION , *GENOMICS , *TUMORS - Abstract
Objective: This study explored family communication about undertaking genomic sequencing, and intentions to communicate pertinent heritable results to family members.Methods: Semi-structured interviews were conducted with cancer patients (n = 53) and their relatives (n = 20) who underwent germline genome sequencing or molecular tumor testing. Interviews were audio-recorded, transcribed and analyzed using thematic analysis.Results: Key themes relevant to family communication about undertaking sequencing included: perceiving family member interest, delaying discussion until results were received, having shared capacity to understand and cope, and having open communication in the family. Intended communication subsequent to receiving results was affected by: disease severity, risk management options, degree of closeness in the family, sense of responsibility, and potential adverse impacts on family. Resource and support needs varied based on the complexity of test results, health professionals' availability, and disease severity. Unique subthemes were identified for specific subgroups.Conclusion: Current findings support the need to assess the impact and resource needs specific to each clinical application of genomic sequencing.Practice Implications: Increasingly sophisticated and complex clinical genomic sequencing warrants development of family-centered interventions and resources to facilitate preference-sensitive communication about genomic sequencing, including disseminating relevant information to family members. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
6. Patient demographic characteristics and risk factors associated with sun protection behaviours in specialist melanoma clinics.
- Author
-
Smith, Juliet, Espinoza, David, Smit, Amelia K., Gallo, Bruna, Smith, Andrea L., Lo, Serigne N., Guitera, Pascale, Martin, Linda K., and Cust, Anne E.
- Abstract
Objective Methods Results Conclusions We investigated the association between sun protection behaviours and demographic and melanoma risk characteristics of patients attending Australian melanoma specialist clinics. This may assist in targeting and tailoring melanoma prevention patient education for people at high‐risk and specific population subgroups.A cross‐sectional analysis of questionnaire data collected from participants attending the dermatology clinics at two major melanoma centres in Sydney, Australia between February 2021 and September 2023. The primary outcome was Sun Protection Habits (SPH) index (a summary score measured as habitual past month use of sunscreen, hats, sunglasses, a shirt with sleeves that covers the shoulders, limiting midday sun exposure and seeking shade, using a Likert scale). The primary analysis considered the SPH index and its component items scored as continuous.Data from 883 people were analysed. Factors associated with less frequent sun protection behaviours overall included male gender, no personal history of melanoma, lower perceived risk, lower calculated 10‐year risk of developing melanoma, and no private health insurance. People aged >61 years reported lower use of sunscreen but higher use of hats and sleeved‐shirts compared with people in the younger age group. There was no difference in overall sun protection behaviours according to family history of melanoma, country of birth or by lifetime melanoma risk among people without a personal history of melanoma.These findings highlight the potential for targeting high‐risk individuals with less frequent use of sun protection for patient education, public health messaging and ultimately improving sun protection behaviours. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Implementation considerations for offering personal genomic risk information to the public: a qualitative study.
- Author
-
Smit, Amelia K., Reyes-Marcelino, Gillian, Keogh, Louise, Dunlop, Kate, Newson, Ainsley J., and Cust, Anne E.
- Abstract
Background: Genomic risk information, based on common genomic susceptibility variants associated with risk of complex diseases such as cancer, may be incorporated into personalised prevention and screening strategies. We aimed to engage with members of the public, who are important stakeholders in this process, to further inform program development and other implementation outcomes such as acceptability and appropriateness.Methods: Semi-structured interviews were undertaken with 30 participants (aged 24-69 years, 50% female) recruited from a pilot trial in which they received personalised genomic risk information for melanoma. We explored participants' views and attitudes towards offering general personal genomic risk information to the broader population. The data were analysed thematically.Results: Two overarching themes relevant to implementation considerations were identified. Firstly, participants' preferences for accepting an offer of genomic risk information were based on family history, disease incidence and the possibility of prevention. Secondly, participants felt that the processes for offering risk information should be based on individual preferences, triaged according to risk and be supported by a health professional trained in genomics.Conclusions: Participants felt that offering personal genomic risk information to the general population to inform prevention and early detection recommendations is acceptable, particularly for common, complex conditions such as cancer. Understanding participants' preferences for receiving genomic risk information will assist with communication strategies and health workforce planning. We anticipate that these findings will contribute to the development of implementation strategies for incorporating genomic risk information into routine clinical practice. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
8. The Melanoma Genomics Managing Your Risk Study randomised controlled trial: statistical analysis plan.
- Author
-
Lo, Serigne N., Smit, Amelia K., Espinoza, David, Cust, Anne E., on behalf of the Managing Your Risk Study Group, Newson, Ainsley J., Morton, Rachael L., Kimlin, Michael, Keogh, Louise, Law, Matthew H., Kirk, Judy, Dobbinson, Suzanne J., Kanetsky, Peter A., Mann, Graham J., Dawkins, Hugh, Savard, Jacqueline, Dunlop, Kate, Trevena, Lyndal, Jenkins, Mark, and Allen, Martin
- Subjects
- *
ULTRAVIOLET radiation , *STATISTICS , *CLINICAL trial registries , *GENOMICS , *MELANOMA , *PHARMACOGENOMICS , *BRAF genes , *ENVIRONMENTAL exposure prevention , *CLINICAL trials , *GENETIC testing , *SKIN tumors , *RISK assessment , *DISEASE susceptibility , *HEALTH behavior , *COST effectiveness , *RESEARCH funding , *DATA analysis - Abstract
Background: The Melanoma Genomics Managing Your Risk Study is a randomised controlled trial that aims to evaluate the efficacy of providing information on personal genomic risk of melanoma in reducing ultraviolet radiation (UV) exposure, stratified by traditional risk group (low or high phenotypic risk) in the general population. The primary outcome is objectively measured total daily Standard Erythemal Doses at 12 months. Secondary outcomes include UV exposure at specific time periods, self-reported sun protection and skin-examination behaviours, psychosocial outcomes, and ethical considerations surrounding offering genomic testing at a population level. A within-trial and modelled economic evaluation will be undertaken from an Australian health system perspective to assess the cost-effectiveness of the intervention.Objective: To publish the pre-determined statistical analysis plan (SAP) before database lock and the start of analysis.Methods: This SAP describes the data synthesis, analysis principles and statistical procedures for analysing the outcomes from this trial. The SAP was approved after closure of recruitment and before completion of patient follow-up. It outlines the planned primary analyses and a range of subgroup and sensitivity analyses. Health economic outcomes are not included in this plan but will be analysed separately. The SAP will be adhered to for the final data analysis of this trial to avoid potential analysis bias that may arise from knowledge of the outcome data.Results: This SAP is consistent with best practice and should enable transparent reporting.Conclusion: This SAP has been developed for the Melanoma Genomics Managing Your Risk Study and will be followed to ensure high-quality standards of internal validity and to minimise analysis bias.Trial Registration: Prospectively registered with the Australian New Zealand Clinical Trials Registry, ID: ACTR N12617000691347 . Registered on 15 May 2017. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
9. MC1R variants and associations with pigmentation characteristics and genetic ancestry in a Hispanic, predominately Puerto Rican, population.
- Author
-
Smit, Amelia K., Collazo-Roman, Marielys, Vadaparampil, Susan T., Valavanis, Stella, Del Rio, Jocelyn, Soto, Brenda, Flores, Idhaliz, Dutil, Julie, and Kanetsky, Peter A.
- Subjects
- *
SKIN cancer , *MELANOCORTIN receptors , *BLOOD sampling , *BIOBANKS , *ANIMAL coloration - Abstract
Skin cancer risk information based on melanocortin-1 receptor (MC1R) variants could inform prevention and screening recommendations for Hispanics, but limited evidence exists on the impact of MC1R variants in Hispanic populations. We studied Hispanic subjects, predominately of Puerto Rican heritage, from Tampa, Florida, US, and Ponce, PR. Blood or saliva samples were collected by prospective recruitment or retrieved from biobanks for genotyping of MC1R variants and ancestry informative markers. Participant demographic and self-reported phenotypic information was collected via biobank records or questionnaires. We determined associations of MC1R genetic risk categories and phenotypic variables and genetic ancestry. Over half of participants carried MC1R variants known to increase risk of skin cancer, and there was diversity in the observed variants across sample populations. Associations between MC1R genetic risk groups and some pigmentation characteristics were identified. Among Puerto Ricans, the proportion of participants carrying MC1R variants imparting elevated skin cancer risk was consistent across quartiles of European, African, and Native American genetic ancestry. These findings demonstrate that MC1R variants are important for pigmentation characteristics in Hispanics and that carriage of high risk MC1R alleles occurs even among Hispanics with stronger African or Native American genetic ancestry. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors.
- Author
-
Smit, Amelia K., Newson, Ainsley J., Morton, Rachael L., Kimlin, Michael, Keogh, Louise, Law, Matthew H., Kirk, Judy, Dobbinson, Suzanne, Kanetsky, Peter A., Fenton, Georgina, Allen, Martin, Butow, Phyllis, Dunlop, Kate, Trevena, Lyndal, Lo, Serigne, Savard, Jacqueline, Dawkins, Hugh, Wordsworth, Sarah, Jenkins, Mark, and Mann, Graham J.
- Subjects
- *
MELANOMA , *RANDOMIZED controlled trials , *CANCER prevention , *MELANOMA diagnosis , *PHYSIOLOGICAL effects of ultraviolet radiation , *GENETICS - Abstract
Background Reducing ultraviolet radiation (UV) exposure and improving early detection may reduce melanoma incidence, mortality and health system costs. This study aims to evaluate the efficacy and cost-effectiveness of providing information on personal genomic risk of melanoma in reducing UV exposure at 12 months, according to low and high traditional risk. Methods In this randomized controlled trial, participants (target sample = 892) will be recruited from the general population, and randomized (1:1 ratio, intervention versus control). Intervention arm participants provide a saliva sample, receive personalized melanoma genomic risk information, a genetic counselor phone call, and an educational booklet on melanoma prevention. Control arm participants receive only the educational booklet. Eligible participants are aged 18–69 years, have European ancestry and no personal history of melanoma. All participants will complete a questionnaire and wear a UV dosimeter to objectively measure their sun exposure at baseline, 1- and 12-month time-points, except 1-month UV dosimetry will be limited to ~250 participants. The primary outcome is total daily Standard Erythemal Doses at 12 months. Secondary outcomes include objectively measured UV exposure for specific time periods (e.g. midday hours), self-reported sun protection and skin-examination behaviors, psycho-social outcomes, and ethical considerations surrounding offering genomic testing at a population level. A within-trial and modelled economic evaluation will be undertaken from an Australian health system perspective to assess the intervention costs and outcomes. Discussion This trial will inform the clinical and personal utility of introducing genomic testing into the health system for melanoma prevention and early detection at a population-level. Trial registration. Australian New Zealand Clinical Trials Registry ACTRN12617000691347. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Public preferences for communicating personal genomic risk information: a focus group study.
- Author
-
Smit, Amelia K., Keogh, Louise A., Hersch, Jolyn, Newson, Ainsley J., Butow, Phyllis, Williams, Gabrielle, and Cust, Anne E.
- Subjects
- *
COMMUNICATION , *ETHNIC groups , *EYE , *FOCUS groups , *HAIR , *PUBLIC health , *RESEARCH funding , *GENOMICS , *ACCESS to information , *CONTROL groups , *HUMAN research subjects , *PATIENT selection , *INDIVIDUALIZED medicine - Abstract
Background: Personalized genomic risk information has the potential to motivate behaviour change and promote population health, but the success of this will depend upon effective risk communication strategies. Objective: To determine preferences for different graphical and written risk communication formats, and the delivery of genomic risk information including the mode of communication and the role of health professionals. Design: Focus groups, transcribed and analysed thematically. Participants: Thirty‐four participants from the public. Methods: Participants were provided with, and invited to discuss, a hypothetical scenario giving an individual's personalized genomic risk of melanoma displayed in several graphical formats. Results: Participants preferred risk formats that were familiar and easy to understand, such as a ‘double pie chart’ and ‘100 person diagram’ (pictograph). The 100 person diagram was considered persuasive because it humanized and personalized the risk information. People described the pie chart format as resembling bank data and food (such as cake and pizza). Participants thought that email, web‐based platforms and postal mail were viable options for communicating genomic risk information. However, they felt that it was important that a health professional (either a genetic counsellor or ‘informed’ general practitioner) be available for discussion at the time of receiving the risk information, to minimize potential negative emotional responses and misunderstanding. Face‐to‐face or telephone delivery was preferred for delivery of high‐risk results. Conclusions: These public preferences for communication strategies for genomic risk information will help to guide translation of genome‐based knowledge into improved population health. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
12. Exploring the Potential Emotional and Behavioural Impact of Providing Personalised Genomic Risk Information to the Public: A Focus Group Study.
- Author
-
Smit, amelia K., Keogh, Louise a., Newson, ainsley J., Hersch, Jolyn, Butow, Phyllis, and Cust, anne E.
- Subjects
- *
HEALTH risk communication , *MEDICAL genomics , *MELANOMA , *FOCUS groups , *BREAST cancer diagnosis , *DISCRIMINATION in insurance - Abstract
Aim: To explore the potential emotional and behavioural impact of providing information on personalised genomic risk to the public, using melanoma as an example, to aid research translation. Methods: We conducted four focus groups in which 34 participants were presented with a hypothetical scenario of an individual's lifetime genomic risk of melanoma (using the term 'genetic risk'). We asked about understanding of genetic risk, who would choose to receive this risk information, potential emotional and behavioural impacts, and other concerns or potential benefits. Data were analysed thematically. Results: Participants thought this risk information could potentially motivate preventive behaviours such as sun protection and related it to screening for other diseases including breast cancer. Factors identified as influencing the decision to receive genetic risk information included education level, children, age and gender. Participants identified potential negative impacts on the recipient such as anxiety and worry, and proposed that this could be mitigated by providing additional explanatory and prevention information, and contact details of a health professional for further discussion. Participants' concerns included workplace and insurance discrimination. Conclusion: Participants recognised the potential for both positive and negative emotional and behavioural impacts related to receiving information on the personalised genomic risk of melanoma. © 2015 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. Precision Public Health Initiatives in Cancer: Proceedings from the Transdisciplinary Conference for Future Leaders in Precision Public Health.
- Author
-
Allen, Caitlin G., Turbitt, Erin, Smit, Amelia K., Passero, Lauren E., Olstad, Dana Lee, Hatch, Ashley, Landry, Latrice, and Roberts, Megan C.
- Subjects
- *
PUBLIC health , *POSTER presentations , *POPULATION health , *PUBLIC interest , *CONFERENCES & conventions - Abstract
Background: Precision public health is an emergent field that requires transdisciplinary collaborations and leverages innovative approaches to improve population health. These opportunities have inspired a new generation of precision public health researchers. Despite burgeoning interest in precision public health, there are limited opportunities for researchers to convene and continue the momentum of this field. Methods: The Transdisciplinary Conference for Future Leaders in Precision Public Health was the among the first events to bring together international researchers and practitioners to learn, network, and agenda set for the future of the field. The conference took place virtually on October 14 and 15, 2021. Results: The conference spanned two days and featured a keynote address, speakers from public health disciplines who are international leaders in precision-based research, networking opportunities, a poster session, and research agenda setting activities. Conclusion: The conference was a critical first step to creating a shared international conversation about precision public health, especially among early-stage investigators. This allowed attendees to continue building their individual skills and international collaborations to support the growth of the field of precision public health. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Acceptability of risk‐stratified population screening across cancer types: Qualitative interviews with the Australian public.
- Author
-
Dunlop, Kate, Rankin, Nicole M., Smit, Amelia K., Salgado, Zofia, Newson, Ainsley J., Keogh, Louise, and Cust, Anne E.
- Subjects
- *
PUBLIC health surveillance , *INTERVIEWING , *QUALITATIVE research , *TUMORS - Abstract
Background: There is mounting evidence of the benefit of risk‐stratified (risk‐tailored) cancer population screening, when compared to standard approaches. However, shifting towards this approach involves changes to practice that may give rise to implementation challenges. Objectives: To explore the public's potential acceptance of risk‐stratified screening across different cancer types, including reducing screening frequency if at low risk and the use of personal risk information, to inform implementation strategies. Method: Semi‐structured interviews were conducted with 40 public participants; half had received personal genomic risk information and half had not. Participants were prompted to consider different cancers. Data were analysed thematically as one dataset. Results: Themes included the following: (a) a sense of security; (b) tailored screening is common sense; (c) risk and the need to take action; (d) not every cancer is the same; and (e) trust and belief in health messages. Both groups expressed similar views. Participants were broadly supportive of risk‐stratified screening across different cancer types, with strong support for increased screening frequency for high‐risk groups. They were less supportive of reduced screening frequency or no screening for low‐risk groups. Findings suggest the public will be amenable to reducing screening when the test is invasive and uncomfortable; be less opposed to forgo screening if offered the opportunity to screen at some stage; and view visible cancers such as melanoma differently. Conclusions: Approaching distinct cancer types differently, tailoring messages for different audiences and understanding reasons for participating in screening may assist with designing future implementation strategies for risk‐stratified cancer screening. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Acceptability and appropriateness of a risk-tailored organised melanoma screening program: Qualitative interviews with key informants.
- Author
-
Dunlop, Kate L. A., Keogh, Louise A., Smith, Andrea L., Aranda, Sanchia, Aitken, Joanne, Watts, Caroline G., Smit, Amelia K., Janda, Monika, Mann, Graham J., Cust, Anne E., and Rankin, Nicole M.
- Subjects
- *
MEDICAL screening , *MEDICAL personnel , *MELANOMA , *EARLY detection of cancer , *HEALTH equity , *ECOLOGICAL risk assessment - Abstract
Introduction: In Australia, opportunistic screening (occurring as skin checks) for the early detection of melanoma is common, and overdiagnosis is a recognised concern. Risk-tailored cancer screening is an approach to cancer control that aims to provide personalised screening tailored to individual risk. This study aimed to explore the views of key informants in Australia on the acceptability and appropriateness of risk-tailored organised screening for melanoma, and to identify barriers, facilitators and strategies to inform potential future implementation. Acceptability and appropriateness are crucial, as successful implementation will require a change of practice for clinicians and consumers. Methods: This was a qualitative study using semi-structured interviews. Key informants were purposively selected to ensure expertise in melanoma early detection and screening, prioritising senior or executive perspectives. Consumers were expert representatives. Data were analysed deductively using the Tailored Implementation for Chronic Diseases (TICD) checklist. Results: Thirty-six participants were interviewed (10 policy makers; 9 consumers; 10 health professionals; 7 researchers). Key informants perceived risk-tailored screening for melanoma to be acceptable and appropriate in principle. Barriers to implementation included lack of trial data, reluctance for low-risk groups to not screen, variable skill level in general practice, differing views on who to conduct screening tests, confusing public health messaging, and competing health costs. Key facilitators included the perceived opportunity to improve health equity and the potential cost-effectiveness of a risk-tailored screening approach. A range of implementation strategies were identified including strengthening the evidence for cost-effectiveness, engaging stakeholders, developing pathways for people at low risk, evaluating different risk assessment criteria and screening delivery models and targeted public messaging. Conclusion: Key informants were supportive in principle of risk-tailored melanoma screening, highlighting important next steps. Considerations around risk assessment, policy and modelling the costs of current verses future approaches will help inform possible future implementation of risk-tailored population screening for melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies.
- Author
-
Modi, Natansh D., Kichenadasse, Ganessan, Hoffmann, Tammy C., Haseloff, Mark, Logan, Jessica M., Veroniki, Areti A., Venchiarutti, Rebecca L., Smit, Amelia K., Tuffaha, Haitham, Jayasekara, Harindra, Manning-Bennet, Arkady, Morton, Erin, McKinnon, Ross A., Rowland, Andrew, Sorich, Michael J., and Hopkins, Ashley M.
- Subjects
- *
INFORMATION sharing , *CLINICAL trials , *PHARMACEUTICAL industry , *SCIENTIFIC discoveries , *MEDICAL personnel - Abstract
Data sharing is essential for promoting scientific discoveries and informed decision-making in clinical practice. In 2013, PhRMA/EFPIA recognised the importance of data sharing and supported initiatives to enhance clinical trial data transparency and promote scientific advancements. However, despite these commitments, recent investigations indicate significant scope for improvements in data sharing by the pharmaceutical industry. Drawing on a decade of literature and policy developments, this article presents perspectives from a multidisciplinary team of researchers, clinicians, and consumers. The focus is on policy and process updates to the PhRMA/EFPIA 2013 data sharing commitments, aiming to enhance the sharing and accessibility of participant-level data, clinical study reports, protocols, statistical analysis plans, lay summaries, and result publications from pharmaceutical industry-sponsored trials. The proposed updates provide clear recommendations regarding which data should be shared, when it should be shared, and under what conditions. The suggested improvements aim to develop a data sharing ecosystem that supports science and patient-centred care. Good data sharing principles require resources, time, and commitment. Notwithstanding these challenges, enhancing data sharing is necessary for efficient resource utilization, increased scientific collaboration, and better decision-making for patients and healthcare professionals. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Validation of Questionnaire and Diary Measures of Time Outdoors Against an Objective Measure of Personal Ultraviolet Radiation Exposure.
- Author
-
Cust, Anne E., Fenton, Georgina L., Smit, Amelia K., Espinoza, David, Dobbinson, Suzanne, Brodie, Alison, Dang, Huong Tran Cam, and Kimlin, Michael G.
- Subjects
- *
PHYSIOLOGICAL effects of ultraviolet radiation , *EXPOSURE dose , *RADIATION dosimetry , *POLYMER films , *PHYSIOLOGICAL effects of solar radiation - Abstract
Abstract: Self‐reported sun exposure is commonly measured using questionnaires or diaries, but there are limited data on their validity, particularly for population subgroups. This research aimed to compare self‐reported sun exposure, measured as (1) habitual time outdoors over the past month on weekends and weekdays and (2) a 4‐day diary measure, against objective measurement of personal ultraviolet radiation using polysulfone film dosimeters. From November 2015 to January 2016, 94 people (22–69 years and living in New South Wales, Australia) completed a questionnaire, 4‐day diary and 4‐day dosimeter measures of overall, weekday and weekend sun exposure. Spearman correlations and Bland–Altman plots were used to measure agreement. The overall weekly correlation was 0.57 (95% confidence interval [CI] 0.44, 0.68) between standard erythemal doses (SEDs) measured by dosimeter and time spent outdoors measured by questionnaire, 0.74 (95% CI 0.66–0.81) between dosimeter and diary, and 0.59 (95% CI 0.48–0.68) between questionnaire and diary measures. Validity was lower for younger people and weekend sun exposure. There was strong correlation between dosimeter and sun diary measures and moderate correlation between dosimeter and questionnaire measures. Daily measurement over a longer period may be required to accurately capture weeklong sun exposure in all population subgroups. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
18. Motivations and Barriers to Participation in a Randomized Trial on Melanoma Genomic Risk: A Mixed-Methods Analysis.
- Author
-
Mercado, Gabriela, Newson, Ainsley J., Espinoza, David, Cust, Anne E., and Smit, Amelia K.
- Subjects
- *
RISK assessment , *MOTIVATION (Psychology) , *PARTICIPATION , *MELANOMA , *RANDOMIZED controlled trials - Abstract
The evolution of polygenic scores for use in for disease prevention and control compels the development of guidelines to optimize their effectiveness and promote equitable use. Understanding the motivations and barriers to participation in genomics research can assist in drafting these standards. We investigated these in a community-based randomized controlled trial that examined the health behavioral impact of receiving personalized melanoma genomic risk information. We examined participant responses in a baseline questionnaire and conducted interviews post-trial participation. Motivations differed in two ways: (1) by gender, with those identifying as women placing greater importance on learning about their personal risk or familial risk, and how to reduce risk; and (2) by age in relation to learning about personal risk, and fear of developing melanoma. A barrier to participation was distrust in the handling of genomic data. Our findings provide new insights into the motivations for participating in genomics research and highlight the need to better target population subgroups including younger men, which will aid in tailoring recruitment for future genomic studies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Independent evaluation of melanoma polygenic risk scores in UK and Australian prospective cohorts*.
- Author
-
Steinberg, Julia, Iles, Mark M., Lee, Jin Yee, Wang, Xiaochuan, Law, Matthew H., Smit, Amelia K., Nguyen‐Dumont, Tu, Giles, Graham G., Southey, Melissa C., Milne, Roger L., Mann, Graham J., Bishop, D. Timothy, MacInnis, Robert J., and Cust, Anne E.
- Subjects
- *
DISEASE risk factors , *MONOGENIC & polygenic inheritance (Genetics) , *MELANOMA , *SINGLE nucleotide polymorphisms , *AGE groups , *CONFIDENCE intervals - Abstract
Summary: Background: Previous studies suggest that polygenic risk scores (PRSs) may improve melanoma risk stratification. However, there has been limited independent validation of PRS‐based risk prediction, particularly assessment of calibration (comparing predicted to observed risks). Objectives: To evaluate PRS‐based melanoma risk prediction in prospective UK and Australian cohorts with European ancestry. Methods: We analysed invasive melanoma incidence in the UK Biobank (UKB; n = 395 647, 1651 cases) and a case‐cohort nested within the Melbourne Collaborative Cohort Study (MCCS, Australia; n = 4765, 303 cases). Three PRSs were evaluated: 68 single‐nucleotide polymorphisms (SNPs) at 54 loci from a 2020 meta‐analysis (PRS68), 50 SNPs significant in the 2020 meta‐analysis excluding UKB (PRS50) and 45 SNPs at 21 loci known in 2018 (PRS45). Ten‐year melanoma risks were calculated from population‐level cancer registry data by age group and sex, with and without PRS adjustment. Results: Predicted absolute melanoma risks based on age and sex alone underestimated melanoma incidence in the UKB [ratio of expected/observed cases: E/O = 0·65, 95% confidence interval (CI) 0·62–0·68] and MCCS (E/O = 0·63, 95% CI 0·56–0·72). For UKB, calibration was improved by PRS adjustment, with PRS50‐adjusted risks E/O = 0·91, 95% CI 0·87–0·95. The discriminative ability for PRS68‐ and PRS50‐adjusted absolute risks was higher than for risks based on age and sex alone (Δ area under the curve 0·07–0·10, P < 0·0001), and higher than for PRS45‐adjusted risks (Δ area under the curve 0·02–0·04, P < 0·001). Conclusions: A PRS derived from a larger, more diverse meta‐analysis improves risk prediction compared with an earlier PRS, and might help tailor melanoma prevention and early detection strategies to different risk levels. Recalibration of absolute risks may be necessary for application to specific populations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Advancing precision public health using human genomics: examples from the field and future research opportunities.
- Author
-
Roberts, Megan C., Fohner, Alison E., Landry, Latrice, Olstad, Dana Lee, Smit, Amelia K., Turbitt, Erin, and Allen, Caitlin G.
- Subjects
- *
PUBLIC health , *HEALTH equity , *GENOMICS , *ENVIRONMENTAL health , *PUBLIC health research , *DATA integration - Abstract
Precision public health is a relatively new field that integrates components of precision medicine, such as human genomics research, with public health concepts to help improve population health. Despite interest in advancing precision public health initiatives using human genomics research, current and future opportunities in this emerging field remain largely undescribed. To that end, we provide examples of promising opportunities and current applications of genomics research within precision public health and outline future directions within five major domains of public health: biostatistics, environmental health, epidemiology, health policy and health services, and social and behavioral science. To further extend applications of genomics within precision public health research, three key cross-cutting challenges will need to be addressed: developing policies that implement precision public health initiatives at multiple levels, improving data integration and developing more rigorous methodologies, and incorporating initiatives that address health equity. Realizing the potential to better integrate human genomics within precision public health will require transdisciplinary efforts that leverage the strengths of both precision medicine and public health. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Who should access germline genome sequencing? A mixed methods study of patient views.
- Author
-
Best, Megan C., Butow, Phyllis, Jacobs, Chris, Savard, Jacqueline, Biesecker, Barbara, Ballinger, Mandy L., Bartley, Nicci, Davies, Grace, Napier, Christine E., Smit, Amelia K., Thomas, David M., and Newson, Ainsley J.
- Subjects
- *
NUCLEOTIDE sequencing , *SCIENTIFIC ability , *FAMILY history (Medicine) , *MEDICAL care surveys - Abstract
Implementation of any new medical test, including germline genome sequencing (GS) to inform cancer risk, should take place only when a test is effective, ethically justifiable and acceptable to a population. Little empirical evidence exists on patient views regarding GS for cancer risk. The aim of this study was to elicit opinions on who should be offered GS and who should pay for it. Participants with a probable genetic basis for their cancer (n = 335) and blood relatives (n = 199) were recruited to undergo GS and invited to complete questionnaires at baseline. A subset (n = 40) also participated in qualitative interviews about their views regarding access to GS to detect cancer risk. Our response rate was 92% for questionnaires and 100% for interviews. Participants expressed high enthusiasm overall for access to GS for those with a family history of cancer and anyone who requested testing, but enthusiasm was lower for universal access, if opting out was possible and finances not an issue. Rationales for these views reflected maximising the sound use of resources. Challenges to introducing community screening via GS to limit cancer burden were raised, including the current limits of science and individual ability to cope with uncertain results. Participants undergoing GS supported cancer risk testing for those with a family history of cancer but were concerned about the challenges of designing and implementing a population‐based GS cancer‐screening program. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. School-based interventions to improve sun-safe knowledge, attitudes and behaviors in childhood and adolescence: A systematic review.
- Author
-
Reyes-Marcelino, Gillian, Wang, Rhona, Gultekin, Sinem, Humphreys, Lauren, Smit, Amelia K., Sharman, Ashleigh R., St Laurent, Andrea G., Evaquarta, Rosa, Dobbinson, Suzanne J., and Cust, Anne E.
- Subjects
- *
CHILDHOOD attitudes , *SCHOOL children , *ADOLESCENCE , *SOCIAL influence , *SKIN cancer , *IMMUNIZATION of children , *SUNRISE & sunset - Abstract
Ultraviolet radiation exposure is the leading cause of skin cancer, and childhood and adolescence is a particularly susceptible life period for exposure. This systematic review assessed whether interventions in elementary and secondary school settings reduced sun exposure, sunburns, and development of melanocytic nevi, and improved sun-safe knowledge, attitudes and sun protection behaviors in childhood and adolescence. A systematic search up to June 2020 of MEDLINE, Embase, CINAHL, Cochrane and ProQuest databases was undertaken, for studies conducted among students in an elementary or secondary school setting that compared an intervention group with a pre-intervention or separate control group. Data were summarized using qualitative synthesis. Pooled effects from meta-analysis with random effects were also reported where appropriate. Sixty-five studies were included (22 randomized, 43 non-randomized). Most studies assessed measures of sun-safe behaviors, knowledge and attitudes (57, 48 and 33 studies, respectively), and observed improved sun protection behaviors and sun-safe knowledge, whereas few studies reduced time in the sun. About half improved participants' attitudes towards tanning desirability. Sunburns and nevus counts were less frequently assessed, but about half of these studies observed a reduction. There was substantial heterogeneity for outcomes except attitudes towards the desirability of tanning (pooled odds ratio from 6 studies: 0.81, 95% confidence interval 0.70-0.94). Key positive intervention features included: elementary school settings, interactive features or multiple components, and incorporating social norm influences. Most studies were classified at high risk of bias. In conclusion, school-based sun-related interventions had positive impacts on behaviors and attitudes among elementary and secondary school children. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resourcesDiscovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.